Skeletal Wellness Institute for Cancer™: References

If you can read this, then your browser cannot interpret Javascript. To take full advantage of what this Web site has to offer, please make sure that you have Javascript enabled in your browser preferences, or update to a browser that supports Javascript. Thank you.

Skeletal Wellness Institute for Cancer™ - Maintaining Bone Health

References

Actonel® (risedronate disodium) [package insert]. North Norwich, NY: Procter & Gamble Pharmaceuticals; 2003.
Adami S. Bisphosphonates in prostate carcinoma. Cancer. 1997;80:1674-1679.
AHCPR Evidence Report/Technology Assessment No. 4, Publication #99-E012. Available at http://www.ahcpr.gov/news/ press/pr1999/prospr.htm.
American Cancer Society. Cancer Facts and Figures 2004. Atlanta, Ga: American Cancer Society; 2004.
Anderson PK, Gill RD. Cox's regression model for counting processes: a large sample study. Ann Stat. 1982;10:1100-1120.
Aparicio A, Gardner A, Tu Y, et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia. 1998;12:220-229.
Aredia® (pamidronate disodium) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002.
Barille-Nion S, Bataille R. New insights in myeloma-induced osteolysis. Leuk Lymphoma. 2003;44:1463-1467.
Barse PM. Issues in the treatment of metastatic breast cancer. Semin Oncol Nurs. 2000;16:197-205.
Beer TM: Prostate cancer. Presented at the 2004 Annual Meeting of the American Society for Clinical Oncology. Available at http://www.CancerConsultants.com. Accessed November 2004.
Beer TM, Pierce WC, Lowe BA, Henner WD. Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol. 2001;12:1273-1279.
Berenson JR, Green MR, Lipton A, Higano CS. Overview of Bone Metastases and Bisphosphonates. Projects in Knowledge. New Currents in Treatment of Bone Metastases: A Case-Based Approach. 2003. Part 1 of 5. Available at http://www.projectsinknowledge.com/oncol/. Accessed November 2004.
Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.
Berenson JR, Lichtenstein A, Porter L, et al, for the Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. NEJM. 1996;334:488-493.
Berenson JR, Lipton A. Bisphosphonates in the treatment of malignant bone disease. Ann Rev Med. 1999;50:237-248.
Bergström I, Gustafsson H, Sjöberg K, Arver S. Changes in bone mineral density differ between gonadotrophin-releasing hormone analogue and surgically castrated men with prostate cancer. Scand J Urol Nephrol. 2004;38:148-152.
Berruti A, Dogliotti L, Terrone C, et al, for the Gruppo Onco Urologico Piemontese, Rete Oncologica Piemontese. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002;167:2361-2367.
Bisphosphonates. Drug Facts and Comparisons. St. Louis, Mo: Wolters Kluwer Health; 2004:343-356.
Body JJ. Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia. 2001;6:477-485.
Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003;97(suppl 3):859-865.
Body JJ. Rationale for the use of bisphosphonates in osteoblastic and osteolytic bone lesions. The Breast. In press.
Body JJ, Bartl R, Burckhardt P, et al, for the International Bone and Cancer Study Group. Current use of bisphosphonates in oncology. J Clin Oncol. 1998;16:3890-3899.
Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90:1133-1137.
Body JJ, Dumon JC, Gineyts E, Delmes PD. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer. 1997;75:408-412.
Body JJ, Mancini I. Bisphosphonates for cancer patients: why, how and when? Support Care Cancer. 2002;10:399-407.
Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949-2954.
Bondronat® (ibandronate sodium) [prescribing information]. Mississauga, Ontario: Hoffman-La Roche Limited; 2004.
Bone HG, Hosking D, Devogelaer JP, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. NEJM. 2004;350:1189-1199.
Boyce SP, Smith MR, Raut MK, et al. Natural history, treatment patterns, and economic burden of cancer therapy induced bone loss (CTIBL) among breast and prostate cancer patients (pts): a study overview. Proc ASCO. 2000;23:785. Abstract 8243.
Boyce BF, Yoneda T, Guide TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer. 1999;6:333-347.
Brown HK, Healey JH. Metastatic cancer to the bone. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol. 2, 6th ed. Philadelphia, Pa: JB Lippincott; 2001:2713-2728.
Brown JE, Neville-Webbe H, Coleman RE. The role of bisphosphonates in breast and prostate cancer. Endocr Relat Cancer. 2004;11:207-224.
Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 1996;17:333-368.
Chang SS. Exploring the effects of luteinizing hormone-releasing agonist therapy on bone health: implication in the management of prostate cancer. Urology. 2003;62(suppl 1):29-35.
Cherny NI, Catane R. European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Attitudes of medical oncologists toward palliative care for patients with advanced and incurable cancer: report on a survey by the European Society of Medical Oncology Taskforce on Palliative and Supportive Care. Cancer. 2003;98:2502-2510.
Clarke NW, McClure J, George NJ. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992;69:64-70.
Clarke NW, McClure J, George NJ. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68:74-80.
Classification and staging. Multiple Myeloma Research Foundation. Available at http://www.multiplemyeloma.org/about_ myeloma/2.06.html. Accessed December 2004.
Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-130.
Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer. 2003;97(suppl):880-886.
Coleman RE. Management of bone metastases. Oncologist. 2000;5:463-470.
Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(suppl 8):1588-1594.
Coleman RE. The clinical use of bone resorption markers in malignant bone disease. Cancer. 2002;94:2521-2531.
Coleman RE, Theriault RL, Smith MR, Rosen LS. The evolving role of bisphosphonates for cancer treatment-induced bone loss [monograph]. Release date June 2003. Available at: http://www.medscope.com/viewprogram/2511_pmt. Accessed November 29, 2004.
Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urol Oncol. 2003;21:1380-1383.
Conde FA, Sarna L, Oka RK, et al. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004;64:335-340.
Cornell CN, Lane JM. Current understanding of osteoconduction in bone regeneration. Clin Orthop. 1998:355(suppl):S267-S273.
Croucher P, Jagder S, Coleman R. The anti-tumor potential of zoledronic acid. Breast. 2003;12(suppl 2):S30-S36.
Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997;157:439-444.
Daniell HW, Dunn SR, Ferguson DW, et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000;163:181-186.
Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. NEJM. 1997;337:670-676.
Dearnaley DP, Sydes MR, Mason MD, et al, and the Mrc Pr05 Collaborators. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J Natl Cancer Inst. 2003;95:1300-1311.
Delmas PD, Balena R, Confravreux E, et al. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15:995-962.
Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer. 2000;88(suppl 12):2919-2926.
Derenne S, Amiot M, Barille S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999;14:2048-2056.
Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol. 2, 6th ed. Philadelphia, Pa: JB Lippincott; 2001:2713-2728.
Diamond TH, Bucci J, Kersley JH, et al. Osteoporosis and spinal fractures in men with prostate cancer: risk factors and effects of androgen deprivation therapy. J Urol. 2004;172:529-532.
Diamond TH, Higano CS, Smith MR, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy. Cancer. 2004;100:892-899.
Diamond TH, Winters J, Smith A, et al. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Cancer. 2001;92:1444-1450.
Didronel® (etidronate disodium) [package insert]. North Norwich, NY: Procter & Gamble Pharmaceuticals; 2002.
Diel IJ, Marschner N , Kindler M, Lange O, Untch M, Hurtz H, Breitbach G, Richter B. Continual oral versus intravenous interval therapy with bisphosphonates in patients with breast cancer and bone metastases (meeting abstract). Proc ASCO. 1999. Abstract 488.
Durie BGM. International Myeloma Foundation Concise Review of the Disease and Treatment Options: Multiple Myeloma. 2003 ed. North Hollywood, Calif: International Myeloma Foundation; 2003.
Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol. 1992;24:159-166.
Ernst DS, Tannock IF, Venner PM, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group Study. Proc ASCO. 2002;21:177a. Abstract 705.
Ernst DS, Tannock IF, Winquist EW, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335-3342.
Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. J Bone Miner Res. 1994;26:95-107.
Falkmer U, Jarhult J, Wersall P, Cavallin-Stahl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol. 2003;42:620-633.
Ferlay J et al. Cancer incidence, mortality, and prevalence. IARC Globocon. 2000.
Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19:80-100.
Fosamax® (alendronate sodium) [package insert]. Merck & Co., Inc; 2003.
Fromigué O, Kheddoumi N, Lomri A, et al. Breast cancer cells release factors that induce apoptosis in human bone marrow stromal cells. J Bone Miner Res. 2001;16:1600-1610.
Fromigué O, Lagneaux L, Body J-J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000;15:2211-2221.
Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82:858-864.
Gaze MN, Kelly CG, Kerr GR, et al. Pain relief and quality of life following radiotherapy for bone metastases: a randomised trial of two fractionation schedules. Radiother Oncol. 1997;45:109-116.
Goltzman D. Discoveries, drugs and skeletal disorders. Nat Rev Drug Discov. 2002;1:784-796.
Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 1997;80:1581-1587.
Green JR. Bisphosphonates in cancer therapy. Curr Opin Oncol. 2002;14:609-615.
Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13.
Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rate models. Pharmacol Toxicol. 1997;80:225-230.
Grethlein S. Multiple myeloma. Emedicine. Available at http://www.emedicine. com/med/topic1521.htm#target1. Accessed December 2004.
Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol. 2003;43:226-232.
Guise TA, Mundy GR. Cancer and bone. Endocr Rev. 1998;19:18-54.
Harvey HA. Aromatase inhibitors in clinical practice: current status and a look to the future. Semin Oncol. 1996;23(suppl 9):33-38.
Hatano T, Oishi Y, Furuta A, et al. Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 2000;86:449-452.
Higano CS. Management of bone loss in men with prostate cancer. J Urol. 2003;170:S59-S63.
Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004;31:331-352.
Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003;21:4042-4057.
Hortobagyi GN. Novel approaches to the management of bone metastases. Semin Oncol. 2003;30(suppl 16):161-166.
Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. NEJM. 1996;335:1785-1791.
Hoskin PJ. Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev. 2003;29:321-327.
International Myeloma Foundation. 2001. Available at http://seer.cancer.gov/csr/1975_2000. Accessed May 2003.
Jagdev SP, Purokit OP, Heatley S, Herling C. Comparison of effects of intravenous pamidronate and oral clodronate symptoms and bone resorption in patients with metastatic cancer. Ann Oncol. 2001;12:1433-1438.
Jemal A, Tiwari RC, Murray T, et al. Cancer Statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
Jensen MP, Karoly P. Pain-specific beliefs, perceived symptom severity, and adjustment to chronic pain. Clin J Pain. 1992;8:123-130.
Kanis JA, McCloskey EV, Powles T, et al. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79:1179-1181.
Kanis JA, Melton LJ 3rd, Christiansen C, et al. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
Kardinal CG. Endocrine therapy of breast cancer. In: Donegan WL, Spratt JS, eds. Cancer of the Breast. 4th ed. Philadelphia, Pa: WB Saunders; 1995.
Kelly WK, Steineck G. Bisphosphonates for men with prostate cancer: sifting through the rubble [editorial]. J Clin Oncol. 2003;21:4261-4262.
Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162:2217-2222.
Krupski TL, Smith MR, Chan Lee W, et al. Fracture risk in men with prostate cancer on androgen deprivation therapy. J Urol. 2004;171:116. Abstract 438.
Krupski TL, Smith MR, Chan Lee W, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101:541-549.
Krupski TL, Smith MR, Chan Lee W, et al. Profile of men with prostate cancer on androgen deprivation therapy at greatest risk of bone complications. Proc ASCO. 2004;23:726. Abstract 8000.
Labrie F. GNRH agonist in prostate cancer. In: GnRH Analogues. The State of the Art. New York, NY: Parthenon Publishing; 1993:103-131.
Lacerna L, Hohneker J. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors. Semin Oncol. 2003;30(suppl 16):150-160.
Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol. 2003;13:698-703.
Lane J. Part 2: benign and malignant bone tumors and soft-tissue sarcomas: orthopaedic surgery, Board Review Manual. Hospital Physician. 1998:3:2-14.
Lane J, Nydick M. Osteoporosis: current modes of prevention and treatment. J Am Acad Orthop Surg. 1999;7:1:19-31.
Lane JM. Osteoporosis: medical prevention and treatment. Spine 1997;22:24S,32S-37S.
Lane JM, Bostrom MP. Bone grafting and new composite biosynthetic graft materials. AAOS Instructional Course Lecture. 1998:47:525-534.
Lane JM, Russell L, Khan SN. Osteoporosis. Clin Orthop. 2000;372:139-150.
Lane JM, Tomin E, Bostrom MPG. Biosynthetic bone grafting. Clin Orthop. 1999;367(suppl):S107-S117.
Liapis D, Argyropoulos A, Kalantzis A, et al. The impact of zoledronic acid to PSA, bone lesions and quality of life of patients with hormone refractory metastatic prostate cancer. Poster session 34: hormone refractory prostate cancer. Presented at the XIXth EAU Congress; March 26, 2004; Vienna, Austria.
Lindsey R, Cosman F. Osteoporosis. In: Braunwald E, Fauci A, Kasper D, et al, eds. Harrison's Principles of Internal Medicine. 15th ed. New York, NY: McGraw-Hill; 2001.
Lindsay R, Silverman S, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323.
Lipton A. Toward new horizons: the future of bisphosphonate therapy. Oncologist. 2004;9(suppl 4):38-47.
Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20(suppl 2):45-54.
Loblaw DA, Mendelson DS, Talcott JA, et al. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22:2927-2941.
Love RR, Mazess RB, Borden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. NEJM. 1992;326:885-886.
Maillefert JF, Sibilia J, Michel F, et al. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999;161:1219-1222.
Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer. 2000;88:6-14.
Mandel K, Atkinson S, Barr RD, Pencharz P. Skeletal morbidity in childhood acute lymphoblastic leukemia. J Clin Oncol. 2004;22:1215-1221.
Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab. 1998;83:1158-1162.
Maxwell C, Swift R, Goode M, et al. Advances in the supportive care of patients with cancer and bone metastases: Nursing implications of zoledronic acid. Clin J Oncol Nurs. 2003;7:403-408.
McCloskey EV, Dunn JA, Kanis JA, et al, on behalf of the Medical Research Council Working Party on Leukaemia in Adults. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035-1043.
Melton LJ III, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol. 2003;169:1747-1750.
Michaelson MD, Marujo RM, Smith MR. Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Clin Cancer Res. 2004;10:2705-2708.
Mincey BA. Osteoporosis in women with breast cancer. Curr Oncol Rep. 2003;5:53-57.
Mittan D, Lee S, Miller E, et al. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656-3661.
Multiple Myeloma Research Foundation. Aredia/Zometa: Bisphosphonates Overview. Available at http://multiplemyeloma.org/treatments/3.06.html. Accessed October 28, 2004.
Multiple Myeloma Research Foundation. Myeloma bone disease. Available at http://www.multiplemyeloma.org/about_myeloma/2.08.html. Accessed December 2004.
Mundy GR. Bisphosphonates as cancer drugs. Hosp Pract. 1999;34-81-94.
Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80:1546-1556.
Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584-593.
Mundy GR. The evolving role of bisphosphonates: cancer treatment–induced bone loss. Oncology. 2004;18(suppl 3):9-10.
Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin Oncol. 2001;28:35-44.
Murray RM, Grill V, Crinis N, et al. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab. 2001;86:4133-4138.
Nakamoto Y, Osman M, Wahl RL. Prevalance and patterns of bone metastases detected with position emission tomography using F-18 FDG. Clin Nucl Med. 2003; 28:302-307.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Cancer Pain. Version 1. 2004. Available at http://www.nccn.org/professionals/physician_gls/PDF/pain.pdf. Accessed September 28, 2004.
National Osteoporosis Foundation. Boning Up. Washington, DC: National Osteoporosis Foundation; 2000.
National Osteoporosis Foundation. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003.
Niesvizky R. Gallium nitrate in multiple myeloma: prolonged survival in a cohort of patients with advanced-stage disease. Semin Oncol. 2003;30(suppl 5):20-24.
O'Connor WJ, Lane JM. The benefits of tai chi in osteoporosis. Am J Sports Med. 1999;1(Sept/Oct).
Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002;168:1005-1007.
Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001;166:1724-1728.
Office of the Surgeon General. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, Md: US Department of Health and Human Services. October 14, 2004. Available at http://www.hhs.gov/surgeongeneral/library/bone health/. Accessed November 19, 2004.
Orr FW, Lee J, Duivenvoorden WC, Singh G. Pathophysiologic interactions in skeletal metastasis. Cancer. 2000;88:2912-2918.
Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. NEJM. 2000;343:604-610.
Orwoll ES. Osteoporosis in men. Endocr Rev. 1995;16:87-116.
Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease: clinical pharmacology and therapeutic use. Drugs. 1993;46:594-617.
Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:59-65.
Pavlakis N, Stockler M. Bisphosphonates for breast cancer (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
Pecherstorfer M, Herrmann Z, Body J-J, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 1996;14:268-276.
Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficiency and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer. 2003;11:539-547.
Peterson MGE, Galsworthy T, Lane J, et al: Maintenance of bone density: outcomes over five years of attendance at an osteoporosis center. J Gerontol Biol Sci Med Sci. 2000;55:M141-M146.
Petrylak DP, Tangen C, Hussain M, et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPC). Proc ASCO. 2004:23:2. Abstract 3.
Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol. 2000;18;1570-1593.
Poor G, Atkinson EJ, Lewallen DG, et al. Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporos Int. 1995;5:419-426.
Powles T, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20:3219-3224.
Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14:78-84.
Powles TJ, McCloskey E, Paterson AHG, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704-708.
Prostate Cancer Foundation. Report to the nation on prostate cancer 2004. Available at http://www.prostatecancerfoundation.org. Accessed December 2004.
Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol. 2003;30:763-775.
Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complication in patients with prostate cancer. J Urol. 2004;171:1537-1542.
Reich CD. Advances in the treatment of bone metastasis. Clin J Oncol Nurs. 2003; 7:641-646.
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. NEJM. 2002;346:653-661.
Riccardi A, Grasso D, Danova M. Bisphosphonates in oncology: physiopathologic bases and clinical activity. Tumori. 2003;89:223-236.
Riggs BL, Melton LJ 3rd. The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone. 1995;17(suppl 5):505S-511S.
Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocr Metab. 2001;86:5252-5255.
Robertson AG, Reed NS, Ralston SH. Effect on oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol. 1995;13:2427-2430.
Roodman GD. Mechanisms of bone metastasis. NEJM. 2004;350:1655-1664.
Rosen LS. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer. Oncology. 2004;18(suppl 3):26-32.
Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98:1735-1744.
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
Rosen LS, Gordon D, Tchekmedyian NS, et al, on behalf of the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621.
Rosen LS, Gordon D, Tohekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial — The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
Ross RW, Small EJ. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002;167:1952-1956.
Rubens RD, Coleman RE. Bone metastases. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, eds. Clinical Oncology. New York, NY: Churchill Livingstone; 1995:643-665.
Saad F, Eastham J, Guise TA, et al. The role of IV bisphosphonates in the management of bone complications related to prostate cancer: a consensus from experts [monograph]. Novartis Oncology. 2004.
Saad F, Gleason DM, Murray R, et al. Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Poster session 34: Hormone refractory prostate cancer. Presented at the XIXth EAU Congress; March 26, 2004; Vienna, Austria.
Saad F, Gleason DM, Murray R, et al. Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. Presented at the American Urological Association Annual Meeting; April 26-May 1, 2003. Abstract 1472.
Saad F, Gleason DM, Murray R, et al, for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.
Saad F, Gleason DM, Murray R, et al, for the Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol. 2004;45:26-34.
Saarto T, Blomqvist C, Valimaki M, et al. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341-1347.
Sachdeva K, Hopper K, Ali S, et al. Chemotherapy causes loss of bone mineral density. Proc ASCO. 2001. Abstract 2986.
Santini D, Vespasiani Gentilucci U, Vincenzi B, et al. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol. 2003;14:1468-1476.
Schildhauer TA, Bennett AP, Wright TM, et al. Intravertebral body reconstruction with an injectable in situ-setting carbonated apatite: biomechanical evaluation of a minimally invasive technique. J Orthop Res. 1999;17:67-72.
Senaratne SG, Pirienov G, Mansi JL, et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000;82:1459-1468.
Skelid® (tiludronate disodium) [package Insert]. New York, NY: Sanofi-Synthelabo Inc; 2002.
Sloan-Kettering Cancer Site. Cancer information; 2004. Available at http://www.mskcc.org/mskcc/html/361.cfm.
Small E, Smith MR, Seaman JJ, et al. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277-4284.
Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 1989;141:85-87.
Smith M, Chan Lee W, Krupski T, et al. Association between androgen deprivation therapy and fracture risk: a population-based cohort study in men with non-metastatic prostate cancer. Proc ASCO. 2004. Abstract 4507.
Smith MR. Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer. J Urol. 2003;170(6 Pt 2):S55-S57; discussion S57-S58.
Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer. 2003;97(suppl 3):789-795.
Smith MR. Management of treatment-related osteoporosis in men with prostate cancer. Cancer Treat Rev. 2003;29:211-218.
Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008-2012.
Smith MR, Goode M, Zietman AL, et al. Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition. J Clin Oncol. 2004;22:2546-2553.
Smith MR, McGovern FJ, Fallon MA, et al. Low bone mineral density in hormone-naïve men with prostate carcinoma. Cancer. 2001;91:2238-2245.
Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. NEJM. 2001;345:948-955.
The US NIH Osteoporosis and Related Bone Diseases-National Resource Center. Available at http://www.osteo.org/.
Theriault RL. Pathophysiology and implications of cancer treatment–induced bone loss. Oncology. 2004;18(suppl 3):11-15.
Theriault RL, Lipton A, Hortobagyi GN, et al, for the Protocol 18 Aredia Breast Cancer Study Group. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol. 1999;17:846-854.
Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997;79:545-550.
Traill ZC, Talbot D, Golding S, Gleeson FV. Magnetic resonance imaging versus radionuclide scintigraphy in screening for bone metastases. Clin Radiol. 1999;54:448-451.
Tripathy D, Lichinitzer M, Lazarev A, et al, on behalf of the MF 4434 Study Group. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004;15:743-750.
Weinfurt KP, Anstrom KJ, Castel LD, et al. Effect of zoledronic acid on clinically meaningful changes in pain associated with metastatic prostate cancer. Proc ASCO. 2004;23:425. Abstract 4680.
Weinfurt KP, Castel LD, Li Y, et al. The impact of skeletal-related events on preferences and health-related quality of life of patients with metastatic prostate cancer. J Urol. 2004;171:42. Abstract 158.
Weinfurt KP, et al. Presented at the European Society for Medical Oncology 27th Congress; October 18-22, 2002; Nice, France. Abstract.
Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs. 2003;63:417-437.
Weston R, Hussain A, Stephenson RN, et al. Changes in bone mineral density in prostate cancer patients receiving hormonal manipulation and testosterone recovery following cessation of long-term LHRH analogues. Presented at the British Association of Urological Surgeons Annual Meeting; June 23-27, 2003; Manchester, UK.
Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;(2):CD002068.
Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastic complications of renal cell carcinoma. Int J Oncol. 2001;19:379-382.
ZOMETA® (zoledronic acid) [package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003.

Home | Glossary | Founding Members

Contact Information | References | Privacy Policy